Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 7 - Drugs for disorders of the blood or the extracellular fluid
Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
10/2007
10/30/2007US7288550 Administering 2-butyl-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine or salts to induce biosynthesis of cytokines such as IFN- alpha and/or TNF- alpha; treating viral diseases
10/30/2007US7288522 Method of promoting erythropoiesis
10/30/2007CA2421548C Amidine inhibitors of serine proteases
10/30/2007CA2213742C Process for preparing factor v-deficient plasma, and a deficient plasma which is obtained in this way
10/30/2007CA2186757C Use of biopolymers for digestive tract injuries treatment
10/30/2007CA2179650C Bisindolemaleimides and their use as protein kinase c inhibitors
10/30/2007CA2161350C Oxygen-reduced aqueous solution of factor viii
10/25/2007WO2007121312A2 Trivalent chromium compounds, compositions and methods of use
10/25/2007WO2007120767A2 Agonist erythropoietin receptor antibodies
10/25/2007WO2007119887A1 ACTIVATING AGENT FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR δ
10/25/2007WO2007119656A1 Tamsulosin-containing percutaneous absorption type preparation
10/25/2007WO2007119623A1 Novel use of g-protein-conjugated receptor and ligand thereof
10/25/2007WO2007118984A1 Use of (s)-roscovitine for manufacturing a medicine
10/25/2007WO2007118423A1 Human recombinant erytheropoietin fusion proteins, preparing methods and uses thereof
10/25/2007US20070249813 recombinant human antibodies containing CDR3 domain having an amino acid sequence with alanine substitutions that specifically bind to human tumor necrosis factor alpha (hTNF alpha ) to treat autoimmune disorders ( rheumatic arthritis, allergy, multiple sclerosis, autoimmune diabetes)
10/25/2007US20070249719 Compounds for the treatment of metabolic disorders
10/25/2007US20070249705 N-(1-(2,3-Dihydro-1H-Inden-5Yl)-2-Oxo-3-Pyrrolidinyl)-Sulfonamide Derivatives for Use as Factor Xa Inhibitors
10/25/2007US20070249696 Compounds for the treatment of metabolic disorders
10/25/2007US20070249676 Cyanoguanidine prodrugs
10/25/2007US20070249623 1-(Indole-6-Carbonyl-D-Phenylglycinyl)-4-(1-Methylpiperidin-4-Yl)Piperazine D-Tartrate
10/25/2007US20070249605 such as methyl 2-(4-hydroxy-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamido)acetate
10/25/2007US20070249578 New amidino derivatives and their use as thrombin inhibitors
10/25/2007US20070249020 Cytokine zcytor17 ligand polypeptides and polynucleotides
10/25/2007US20070248685 crosslinking gelatin with glutaraldehyde crosslinker in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran; useful for providing hemostasis at surgical bleeding sites and traumatic bleeding site
10/25/2007US20070248676 Use of nitric oxide adducts
10/25/2007US20070248663 Utilization of Dialkylfumerates
10/25/2007US20070248662 Immunosuppressants; for use in transplantation medicine or treatment of autoimmune diseases such as polyarthritis but not psoriatitc arthritis; micro-tablets, pellets
10/25/2007US20070248617 Medical Uses of Carrier Conjugates of Non-Human Tnf -Peptides
10/25/2007US20070248598 Recombinant anti-VLA4 antibody molecules
10/25/2007US20070248590 Modulators of CDC2-like kinases (CLKS) and methods of use thereof
10/25/2007DE102006020492A1 Verwendung von Acetylsalicylsäure (ASS) beim Einsatz einer Membranlunge Use of acetylsalicylic acid (ASA) with the use of a membrane lung
10/25/2007CA2650404A1 Fused ring thrombin receptor antagonists
10/25/2007CA2650131A1 Agonist erythropoietin receptor antibodies
10/25/2007CA2649735A1 Activating agent for peroxisome proliferator activated receptor .delta.
10/25/2007CA2649710A1 Use of opioid antagonists to attenuate endothelial cell proliferation and migration
10/25/2007CA2649384A1 Erythropoietin receptor agonists
10/25/2007CA2649103A1 Trivalent chromium compounds, compositions and methods of use
10/25/2007CA2647694A1 Use of (s)-roscovitine for manufacturing a medicine
10/24/2007EP1847537A1 Dicarboxamide derivatives
10/24/2007EP1847527A1 Novel benzamidine compound
10/24/2007EP1847271A2 Water-absorbent polymers and their use as a medicament
10/24/2007EP1847269A1 Utilisation of acetyl salicylic acid (ASA) when using a membrane lung
10/24/2007EP1847268A1 Multiple unit oral sustained release preparation and process for production of the same
10/24/2007EP1845961A1 Prevention and treatment of thromboembolic disorders
10/24/2007EP1845951A2 Embolization using poly-4-hydroxybutyrate particles
10/24/2007EP1424334B1 Quinazolinone derivative
10/24/2007EP1207860B1 Controlled release pellet formulation
10/24/2007CN101061135A Synthetic peptides capable of reducing or removing eye-bag formed under lower orbital and their application in cosmetic or dermo-phamaceutical composition
10/24/2007CN101058601A Horseshoe crab anti-endotoxin factor analogue peptide molecule, synthetic method and use thereof
10/24/2007CN101058549A 4-methoxy-1,3-phenyl disubstituted amide derivative
10/24/2007CN101057939A Traditional Chinese medicinal preparation with heat-clearing, blood-cooling, clots dispersing and hemostatic function and its preparation method
10/24/2007CN101057912A Medicine for treating hepatitis and cirrhosis ascites and its preparation method
10/24/2007CN101057908A Heart and brain health dispersion tablet and its preparation method
10/24/2007CN101057905A Microwave extraction method for cordate houttuynia total flavones
10/24/2007CN101057863A Medicine for changing blood quality, preparation method and application
10/24/2007CN101057859A Depolymerization glycosaminoglycan extracted from sea cucumber composition and its preparation method and application
10/24/2007CN101057853A Antiadhesive carbohydrates
10/24/2007CN101057672A Chinese angelica ricefield eel porridge for blood-enriching
10/24/2007CN101057666A Crisp fish with rose
10/24/2007CN101057619A Help producing saliva and slaking thirst, softening blood vessel, promoting blood circulation health tea
10/24/2007CN100344648C Cyclosporine analogue mixtures and their use as immunomodulating agents
10/24/2007CN100344632C 稠合的呋喃化合物 Fused furan compound
10/24/2007CN100344616C Compounds for the treatment of metabolic disorders
10/24/2007CN100344300C Cyclodextrin super molecular composition of Chinese medicine giant knutweed rhizome and its preparing method
10/24/2007CN100344279C Application of schisanhenol for preparing medicine for treating ischemic brain apoplexy
10/23/2007US7285676 Synthesis of chiral 2-alkyl amino acids
10/23/2007US7285670 4,5-Dihydro-2-(2,4-dihydroxyphenyl)-4-methyl-thiazole-4(S)-carboxylic acid by coupling a mono- or polyalkoxybenzonitrile with a cysteine ester and alkylating the thiazoline ring at the 4-carbon position; preferably a phase transfer agent such as N-9-anthracenylmethylcinchonidinium chloride is used
10/23/2007US7285668 At a concentration of 0.1-0.5 g/ml. at 0-35 degrees C. from a C1-4 alkyl acetate solution; preservation stability
10/23/2007US7285664 Heterocyclic or benzenic derivatives of lipoic acid, their preparation and their use as medicaments
10/23/2007US7285635 Reducing the antigenicity of a proteinaceous compound while maintaining the compound's biological activity
10/23/2007US7285556 Antiproliferative agents; hematologic, nervous system, autoimmune diseases; osteoporosis, viral infections
10/23/2007US7285549 Sulfamides and their use as endothelin receptor antagonists
10/23/2007US7285547 E.g., N'-hydroxy-3-((1-((2-methyl-1-piperidinyl)carbonyl)-2-(2 -naphthylsulfonyl)hydrazino)methyl)benzenecarboximidamide
10/23/2007US7285524 Allo and auto-reactive T-cell epitopes
10/23/2007US7285292 Adding an EDTA/NaOH mixture to acontainer and subsequently adding at least one metal compound; adding Na2SeO3 to the container to obtain the trace element solution; improve the trace mineral status of an animal
10/23/2007CA2271697C Tissue type plasminogen activator (t-pa) variants: compositions and methods of use
10/23/2007CA2244209C Improved concentrated injection and infusion solutions for intravenous administration
10/23/2007CA2191612C A process for preparing cardiodilatin fragments; highly purified cardiodilatin fragments and intermediate products for the preparation of same
10/18/2007WO2007117621A1 Use of combination preparations containing thrombin receptor antagonists for treating cardiovascular disorders
10/18/2007WO2007117469A2 Compositions of less immunogenic and long-circulating protein-lipid complexes
10/18/2007WO2007116916A1 Liquid drug preparation for oral administration
10/18/2007WO2007116901A1 Novel arylamide derivative
10/18/2007WO2007115473A1 Pyrrole derivatives inhibitors, their curative uses
10/18/2007WO2007115376A1 Anti-angiogenic agents and methods of their use
10/18/2007WO2007022165B1 Factor xa inhibitor inclusion complex with cyclodextrin
10/18/2007WO2006103545A8 4-piperazinylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors
10/18/2007WO2006103544A8 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
10/18/2007US20070244303 comprising an Fc region derived from a human IgG heavy chain, wherein the Fc region lacks effector function; for the reduction of a deleterious immune response; idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia
10/18/2007US20070244172 Compounds for the treatment of metabolic disorders
10/18/2007US20070244171 Compounds for the treatment of metabolic disorders
10/18/2007US20070244141 Compounds for the treatment of metabolic disorders
10/18/2007US20070244118 Cyclic Amide Derivative, and Its Production and Use
10/18/2007US20070244068 2',3'-O-methylenestyryl-5'-alpha-(carboxymethylenephosphono)-N6-ethylaminocarbonyl-adenosine phosphate; modified mononucleoside phosphate by attaching degradation-resistant substituent on terminal phosphate; increase rate & total amount of mucin secretion; epithelial tissue, platelet aggregation diseases
10/18/2007US20070244047 Albumin fusion proteins
10/18/2007US20070243588 Blood coagulation factor; nucleotide sequence encodes polypeptide; amino acid sequence differs in 1-15 amino acid residues and comprises an introduced in vivo N-glycosylation site; substitution V253N; coagulation related disorders
10/18/2007US20070243189 Blood VEGF level-lowering agent containing IL-6 antagonist as the active ingredient
10/18/2007US20070243165 Granulocyte colony stimulating factor obtained from eggs laid by transgenic avians having newly described G-CSF glycosylation patterns; gene expression of exogenous proteins
10/18/2007CA2648613A1 Use of combination preparations containing thrombin receptor antagonists for treating cardiovascular disorders
10/17/2007EP1845106A1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction
10/17/2007EP1845090A1 Amide compound and thrombopoietin receptor activator
1 ... 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 ... 671